Haleon (HLN)
Bid | 10.32 |
Market Cap | 46.55B |
Revenue (ttm) | 11.23B |
Net Income (ttm) | 1.44B |
EPS (ttm) | 0.42 |
PE Ratio (ttm) | 24.58 |
Forward PE | 23.64 |
Analyst | Buy |
Ask | 10.33 |
Volume | 9,073,855 |
Avg. Volume (20D) | 11,590,393 |
Open | 10.40 |
Previous Close | 10.15 |
Day's Range | 10.30 - 10.46 |
52-Week Range | 8.12 - 10.80 |
Beta | 0.23 |
About HLN
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensod...
Analyst Forecast
According to 1 analyst ratings, the average rating for HLN stock is "Buy." The 12-month stock price forecast is $10.95, which is an increase of 6.09% from the latest price.
Stock Forecasts
3 weeks ago · proactiveinvestors.co.uk
Does defensive Haleon have a cure for the current market blues?Citi believes Haleon PLC (LSE:HLN, NYSE:HLN) is well positioned for the current uncertain climate, describing the consumer healthcare group as a solid defensive play for investors concerned about rece...

1 month ago · seekingalpha.com
Haleon: A Defensive Play That Makes Sense Amidst The Stock Market Sell-OffAs a hybrid healthcare and consumer staple stock, Haleon offers plenty of stability amidst the current market volatility, with its Power Brands driving strong organic growth. Room for expanding margin...